WASHINGTON (Reuters)- U.S. Food and Drug Administration chief, Scott Gottlieb,
criticized pharmacy benefit managers, health insurers and drugmakers on Wednesday for «Kabuki drug - pricing constructs» that profit the industry at the expense of consumers.
But the most provocative takeaway from the client note is how it could disrupt the oft -
criticized middlemen in the prescription drug realm,
pharmacy benefit managers, or PBMs — which I wrote about recently here.